Virtu KCG Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Virtu KCG Holdings’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$591K	Buy	+70,591	New	+$663K	0.02%	990
2017 Q1	–	Sell	-1,121	Closed	-$5K	–	3602
2016 Q4	$5K	Sell	1,121 -95	-8%	-$424	﹤0.01%	3327
2016 Q3	$7K	Buy	1,216 +182	+18%	+$1.14K	﹤0.01%	2991
2016 Q2	$7K	Buy	+1,034	New	+$8.26K	﹤0.01%	2866
2015 Q2	–	Sell	-1,378	Closed	-$25K	–	3657
2015 Q1	$25K	Sell	1,378 -389	-22%	-$7.62K	﹤0.01%	2930
2014 Q4	$33K	Buy	+1,767	New	+$38K	﹤0.01%	3521
2014 Q3	–	Sell	-1,328	Closed	-$48K	–	3945
2014 Q2	$48K	Buy	+1,328	New	+$53.6K	﹤0.01%	3438

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu KCG Holdings's PLX Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Protalix BioTherapeutics (PLX) in Q2 2017: 70,591 shares worth $591K. The stake represents 0.02% of the portfolio and ranks #990 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in PLX as recently as Q4 2016.

Virtu KCG Holdings first reported a position in PLX in Q2 2014 and has held it in 7 quarters since. 34 funds tracked by Wall St. Rank hold PLX as of Q2 2017.

Virtu KCG Holdings held 70,591 shares of Protalix BioTherapeutics worth $591K as of Q2 2017.
Protalix BioTherapeutics was a new Virtu KCG Holdings position in Q2 2017.
Protalix BioTherapeutics made up 0.02% of Virtu KCG Holdings's portfolio in Q2 2017, its #990 holding.
Virtu KCG Holdings first reported a position in Protalix BioTherapeutics in Q2 2014 and has held it in 7 quarters since.
34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.